The first phase 3 data with UCB’s key pipeline drug bimekizumab ... Patients in the study had at least 10% of their body covered with psoriasis at enrolment. The trial provides “strong ...
In this particular study, the Sensor Dot will be used to "measure ... “In partnership with Byteflies, UCB is excited to be at the forefront of next generation wearables, collaborating to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback